BioCentury
ARTICLE | Company News

AbbVie successor to Humira in psoriasis gains FDA approval

April 24, 2019 12:17 AM UTC

With Humira set to face increasing biosimilar competition internationally this year, AbbVie notched its first U.S. approval for a successor to the blockbuster, Skyrizi risankizumab-rzaa, late Tuesday. FDA approved the IL-23 inhibitor to treat plaque psoriasis, one of at least 10 indications on Humira adalimumab’s label.

AbbVie plans to launch Skyrizi in early May at a wholesale acquisition cost (WAC) of $59,000...